These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 3833682)
1. Immunotherapy of Ehrlich ascites carcinoma (EAC) with antiserum to modified EAC. Das AK; Roy DK Indian J Exp Biol; 1985 Nov; 23(11):641-3. PubMed ID: 3833682 [No Abstract] [Full Text] [Related]
2. A naturally occurring complement dependent human IgM macroglobulin inhibitory to Ehrlich ascites tumor cells. Goff MM; Armentrout SA J Clin Lab Immunol; 1982 Dec; 9(3):163-7. PubMed ID: 7166749 [TBL] [Abstract][Full Text] [Related]
3. Specific and non-specific immunotherapy of Ehrlich Ascites Carcinoma in mice. Jakóbisiak M; Kańtoch M; Lasek W; Dobaczewska H; Obłakowski P Folia Biol (Krakow); 1982; 30(3-4):91-7. PubMed ID: 7166197 [No Abstract] [Full Text] [Related]
4. In vivo suppression of Ehrlich ascites carcinoma by human antibody-dependent splenocytes. Dobaczewska H Neoplasma; 1984; 31(2):165-8. PubMed ID: 6717686 [TBL] [Abstract][Full Text] [Related]
6. A spectrophotometric quantitation of cytotoxic action of antiserum and complement by trypan blue. Saijo N Immunology; 1973 Apr; 24(4):683-90. PubMed ID: 4706564 [TBL] [Abstract][Full Text] [Related]
7. [Immunogenicity of cancer-associated and cancer-specific antigens]. del Pozo AM; Valladares Y; Alvarez-Rodríguez Y; Alvarez-Noves J Rev Esp Oncol; 1982; 29(4):685-700. PubMed ID: 6927369 [TBL] [Abstract][Full Text] [Related]
9. Ehrlich ascites cells activate the alternative pathway of the human complement system. Betz M; Hänsch GM; Shin ML Immunobiology; 1984 May; 166(4-5):397-402. PubMed ID: 6237046 [TBL] [Abstract][Full Text] [Related]
10. Tumour microenvironment studies open new perspectives for immunotherapy. Verloes R; Kanarek L Arch Int Physiol Biochim; 1976 Apr; 84(2):420-2. PubMed ID: 71078 [No Abstract] [Full Text] [Related]
11. A vaccine and immune serum for ascites tumor of mice and therapy of skin tumors. Ryu E Dev Biol Stand; 1977 Apr 13-15; 38():381-5. PubMed ID: 608527 [TBL] [Abstract][Full Text] [Related]
12. Natural antibodies against the Ehrlich ascites mouse tumour in sera of irradiated goats, identified by complement consumption. Oravec C; Cambelová J Neoplasma; 1971; 18(2):161-72. PubMed ID: 5577314 [No Abstract] [Full Text] [Related]
13. [Histochemical studies on the effect of antibody and serum factors on ascites tumor cells and mast cells]. Keller R Bibl Haematol; 1967; 27():95-101. PubMed ID: 4233209 [No Abstract] [Full Text] [Related]
14. Influence of immunosuppressive pretreatment on the survival of mice challenged with Ehrlich ascites carcinoma (EAC). Jakóbisiak M; Lasek W; Kańtoch M; Rozmysłowicz T Neoplasma; 1980; 27(2):147-50. PubMed ID: 7393355 [TBL] [Abstract][Full Text] [Related]
15. Suppression of Ehrlich ascites tumor growth by immunization with ganglioside GT1b of its origin, its IgM antibody or anti-idiotype of the anti-GT1b IgM. Saha S; Mondal S Indian J Exp Biol; 2000 Dec; 38(12):1207-16. PubMed ID: 11411041 [TBL] [Abstract][Full Text] [Related]
16. The role of alpha-difluoromethyl ornithine as an adjuvant to immunotherapy in mice bearing transplantable tumors. Chowdhury SR; Guha S; Sen U Neoplasma; 1994; 41(3):159-61. PubMed ID: 7935984 [TBL] [Abstract][Full Text] [Related]
17. [Preventive immunization and immunotherapy of Ehrlich carcinoma and Crocker sarcoma in mice]. Zatula DG Biull Eksp Biol Med; 1969; 67(1):62-4. PubMed ID: 5404408 [No Abstract] [Full Text] [Related]
18. [The effect of antitumor vaccine on the recurrence of solid tumors in mice subjected to surgery]. Zatula DG; Bikhunov VL; Zagoruĭko EE Eksp Onkol; 1984; 6(1):47-9. PubMed ID: 6499731 [TBL] [Abstract][Full Text] [Related]
20. Natural antibodies in normal human sera againist the Ehrlich mouse ascites tumour identified with the aid of complement components, utilizing classical reagents. Oravec C; Cambelová J Neoplasma; 1971; 18(2):141-59. PubMed ID: 5577313 [No Abstract] [Full Text] [Related] [Next] [New Search]